. 2015 Sep 1;192(5):551–558. doi: 10.1164/rccm.201503-0426OC

Table 4.

Baseline Comparisons across Sexes

Characteristic	Male (n = 520)		Female (n = 680)		P Value
Characteristic	n	Mean (95% CI)	n	Mean (95% CI)	P Value
Age, yr^*	520	31.3 (30.5–32.2)	680	31.9 (31.2–32.7)	0.304
Nonwhite race^†	520	177 (34.0)	680	228 (33.5)	0.853
BMI, kg/m²^*	520	26.3 (25.9–26.7)	680	26.8 (26.3–27.4)	0.131
A.M. peak flow, L/min^*	520	508.2 (498.8–517.6)	679	379.4 (373.3–385.4)	<0.001^‡
P.M. peak flow, L/min^*	520	526.4 (517.2–535.7)	679	394.5 (388.6–400.4)	<0.001^‡
FEV₁, L^*	520	3.45 (3.39–3.51)	680	2.63 (2.59–2.68)	<0.001^‡
FEV₁ % predicted^*	520	81.1 (80.0–82.2)	680	84.5 (83.5–85.6)	<0.001^‡
Albuterol 2-puff reversibility^§	142	8.78 (4.79–13.47)	186	7.41 (3.64–14.39)	0.406
Maximum reversibility^§	163	10.57 (6.92–18.31)	220	9.82 (5.82–16.56)	0.170
PC₂₀, mg/ml^§	475	1.23 (0.54–3.27)	644	1.0 (0.38–3.34)	0.029^‡
Daily symptom score, 0 = absent–3 = severe^§	520	0.20 (0.06–0.42)	678	0.20 (0.06–0.47)	0.407
Daily β-agonist rescue puffs, # of puffs^§	128	0.86 (0.11–1.96)	179	0.57 (0.08–2.0)	0.555
Exhaled nitric oxide, ppb^§	276	14.3 (9.0–21.7)	403	15.0 (10.3–24.3)	0.100
Asthma quality-of-life score, 1 = worst–7 = best^§	432	5.85 (5.28–6.38)	603	5.82 (5.16–6.31)	0.074
IgE, IU/ml^§	176	176.5 (67.5–355.0)	274	147.5 (51.0–318.0)	0.164
Sputum eosinophils^§	258	0.80 (0.20–2.90)	346	0.40 (0.0–1.60)	0.017^‡
Blood eosinophils^§	185	200.0 (120.0–312.0)	283	200.0 (103.0–310.0)	0.315
Treatment failure^†	520	61 (11.7)	680	103 (15.2)	0.088

Definition of abbreviations: BMI = body mass index; CI = confidence interval; PC₂₀ = methacholine provocative concentration required to produce a 20% decline in FEV₁.

All baseline comparisons are based on unique subjects across all studies using the most recent study data for subjects in multiple studies, with treatment failures taking precedence.

Two-sample t test, mean (95% CI).

^{^†}

Chi-square test, frequency (percentage).

^{^‡}

P < 0.05.

^{^§}

Wilcoxon rank sum test, median (quartile 1–quartile 3).